Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.60 |
| ▸ | FLT1 | P17948 | 13/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 4/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119392 | 0.89 | EGFR (0.62) | EGFRFLT1KDRSYKPRKCQ | |
| SCHEMBL7115466 | 0.88 | FLT1 (0.74) | EGFRFLT1KDRPRKCQ | |
| SCHEMBL7127649 | 0.85 | EGFR (0.58) | EGFRFLT1KDRSYKVCP | |
| SCHEMBL7118647 | 0.85 | EGFR (0.64) | EGFRFLT1KDRSYKPRKCQ | |
| SCHEMBL7124381 | 0.85 | EGFR (0.71) | EGFRFLT1KDRSYKPRKCQ | |
| SCHEMBL7124392 | 0.85 | EGFR (0.63) | EGFRFLT1KDRSYKPRKCQ | |
| SCHEMBL7124553 | 0.84 | EGFR (0.61) | EGFRFLT1KDRSYKPRKCQ | |
| SCHEMBL7126927 | 0.84 | FLT1 (0.73) | EGFRFLT1KDR | |
| SCHEMBL7125165 | 0.84 | SYK (0.64) | EGFRFLT1SYK | |
| SCHEMBL7118693 | 0.83 | EGFR (0.59) | EGFRFLT1KDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | claimed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | claimed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | EGFR 2961/4885FLT1 1043/4885KDR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.